Association of interleukin-6 (rs1800796) but not transforming growth factor beta 1 (rs1800469) with serum calcium levels in osteoporotic patients

Gene ◽  
2018 ◽  
Vol 671 ◽  
pp. 21-27 ◽  
Author(s):  
Hajar Eftekhari ◽  
Seyyed Reza Hosseini ◽  
Hadis Pourreza Baboli ◽  
Maryam Mafi Golchin ◽  
Laleh Heidari ◽  
...  
Keyword(s):  
Growth Factor ◽  
Serum Calcium ◽  
Transforming Growth Factor Beta ◽  
Interleukin 6 ◽  
Transforming Growth Factor ◽  
Growth Factor Beta

Immunoexpression of Transforming Growth Factor Beta (TGF-ß) And Interleukin-6 (IL-6) in Oral Lichen Planus

2014 ◽  
Vol 117 (2) ◽  
pp. e195-e196
Author(s):  
THÂMARA MANOELA MARINHO BEZERRA ◽  
MÁRCIA CRISTINA DA COSTA MIGUEL ◽  
BÁRBARA VANESSA DE BRITO MONTEIRO ◽  
LUÍZ CARLOS ALVES ◽  
MARIA ALICE RAMALHO DE SÁ LEITE ◽  
...  
Keyword(s):  
Growth Factor ◽  
Lichen Planus ◽  
Transforming Growth Factor Beta ◽  
Interleukin 6 ◽  
Oral Lichen Planus ◽  
Transforming Growth Factor ◽  
Growth Factor Beta ◽  
Oral Lichen

scholarly journals Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis

2018 ◽  
Vol 77 (9) ◽  
pp. 1362-1371 ◽  
Author(s):  
Christopher P Denton ◽  
Voon H Ong ◽  
Shiwen Xu ◽  
Haiyin Chen-Harris ◽  
Zora Modrusan ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Interleukin 6 ◽  
Transforming Growth Factor ◽  
Expression Profiles ◽  
Dermal Fibroblasts ◽  
Sequencing Analysis ◽  
Growth Factor Beta

ObjectivesSkin fibrosis mediated by activated dermal fibroblasts is a hallmark of systemic sclerosis (SSc), especially in the subset of patients with diffuse disease. Transforming growth factor-beta (TGFβ) and interleukin-6 (IL-6) are key candidate mediators in SSc. Our aim was to elucidate the specific effect of IL-6 pathway blockade on the biology of SSc fibroblasts in vivo by using samples from a unique clinical experiment—the faSScinate study—in which patients with SSc were treated for 24 weeks with tocilizumab (TCZ), an IL-6 receptor-α inhibitor.MethodsWe analysed the molecular, functional and genomic characteristics of explant fibroblasts cultured from matched skin biopsy samples collected at baseline and at week 24 from 12 patients receiving placebo (n=6) or TCZ (n=6) and compared these with matched healthy control fibroblast strains.ResultsThe hallmark functional and molecular-activated phenotype was defined in SSc samples and was stable over 24 weeks in placebo-treated cases. RNA sequencing analysis robustly defined key dysregulated pathways likely to drive SSc fibroblast activation in vivo. Treatment with TCZ for 24 weeks profoundly altered the biological characteristics of explant dermal fibroblasts by normalising functional properties and reversing gene expression profiles dominated by TGFβ-regulated genes and molecular pathways.ConclusionsWe demonstrated the exceptional value of using explant dermal fibroblast cultures from a well-designed trial in SSc to provide a molecular framework linking IL-6 to key profibrotic pathways. The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases.Trial registration numberNCT01532869; Post-results.

Sign in / Sign up

Export Citation Format

Share Document